Final analysis of the ALTTO trial: adjuvant trastuzumab in sequence or in combination with lapatinib in patients with HER2-positive early breast cancer [BIG 2-06/NCCTG N063D (Alliance)]
With a longer follow-up, no significant improvement was observed in DFS in patients treated with dual anti-HER2 blockade with lapatinib + trastuzumab compared to trastuzumab alone. The 10-year survival rates for the combination group are consistent with other studies that have explored dual anti-HER2 therapy.
Authors
- Shona Fielding (ORCID: https://orcid.org/0000-0001-5363-8188)
- Serena Di Cosimo (ORCID: https://orcid.org/0000-0002-4666-8052)
- Jerzy Tujakowski
- G. Werutsky
- Judith M. Bliss (ORCID: https://orcid.org/0000-0001-7957-7424)
- David Cameron (ORCID: https://orcid.org/0000-0002-2717-7979)
- Sarra El-Abed (ORCID: https://orcid.org/0000-0002-8783-9671)
- Johannes Holtschmidt (ORCID: https://orcid.org/0000-0002-2723-1154)
- Janine Lombard (ORCID: https://orcid.org/0000-0002-9551-0542)
- S.-B. Kim
- C.-S. Huang
- Judith R. Kroep (ORCID: https://orcid.org/0000-0003-2671-1903)
- E. de Azambuja
- Julie R. Gralow (ORCID: https://orcid.org/0000-0003-3837-9928)
- I. Krop
- Alvaro Moreno‐Aspitia (ORCID: https://orcid.org/0000-0002-2317-2580)
- M. Untch
- Susan Ellard (ORCID: https://orcid.org/0000-0001-5757-9787)
- Larissa A. Korde (ORCID: https://orcid.org/0000-0001-9393-7019)
- D.W. Hillman
- Henry Gómez (ORCID: https://orcid.org/0000-0002-3415-9701)
- Richard J. Rodeheffer (ORCID: https://orcid.org/0000-0001-7305-805X)
- Rebecca Roylance (ORCID: https://orcid.org/0000-0003-1453-6343)
- A.S. Knop
- Saranya Chumsri (ORCID: https://orcid.org/0000-0001-7117-1446)
- N Ben Baruch
- Sherko Küemmel
- Frederieke van Duijnhoven (ORCID: https://orcid.org/0000-0003-3694-4049)
- L. Moscetti
- Ciara M. Kelly (ORCID: https://orcid.org/0000-0002-4393-8088)
- John Townend (ORCID: https://orcid.org/0000-0001-5455-2562)
- M. Piccart-Gebhart
- A.C. Wolff
- F. Boyle
- Antonella Ferro (ORCID: https://orcid.org/0000-0003-4109-6769)
- A. Choudhury
- Binghe Xu (ORCID: https://orcid.org/0000-0002-0234-2747)
- M. Colleoni (ORCID: https://orcid.org/0000-0002-3920-1833)
- István Láng (ORCID: https://orcid.org/0009-0004-3365-9677)
- Robin McConnell
- María Ángeles Vicente
- RD Gelber
Institutions
- Ulsan College (KR)
- American Society of Clinical Oncology (US)
- Mayo Clinic (US)
- Institute of Cancer Research (GB)
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Leiden University Medical Center (NL)
- Kelowna General Hospital (CA)
- Jacksonville College (US)
- Asan Medical Center (KR)
- Institut Jules Bordet (BE)
- WinnMed (US)
- Copenhagen University Hospital (DK)
- Edinburgh Cancer Research (GB)
- Yale Cancer Center (US)
- The Netherlands Cancer Institute (NL)
- Breast International Group (BE)
- University of Ulsan (KR)
- Novartis (India) (IN)
- Holy Family Hospital Nazareth (IL)
- Sidney Kimmel Cancer Center (US)
- Frontier Agriculture (United Kingdom) (GB)
- Instituto Nacional de Enfermedades Neoplásicas (PE)
- German Breast group (DE)
- National Taiwan University Hospital (TW)
- National Cancer Institute (US)
- Mayo Clinic in Florida (US)
- Istituti di Ricovero e Cura a Carattere Scientifico (IT)
- European Institute of Oncology (IT)
Publication Details
- Journal
- ESMO Open
- Published
- 2024-10-17
- DOI
- https://doi.org/10.1016/j.esmoop.2024.103938
- Citations
- 5
- Primary Topic
- HER2/EGFR in Cancer Research
- Type
- article
- Field-Weighted Citation Impact
- 1.41
Funders
- Pfizer
- AstraZeneca
- GlaxoSmithKline
- Novartis
- Roche
- Gilead Sciences
- American College of Radiology Imaging Network
- Meso Scale Diagnostics
- ECOG-ACRIN Cancer Research Group
- Canadian Cancer Society
- Canadian Cancer Society
- National Institutes of Health
- National Cancer Institute